Precede Biosciences Raises $83.5M to Scale Blood-Based Precision Diagnostics Platform for Next-Generation Cancer Therapies
核心洞察
Precede Biosciences (搜索) secured $83.5 million in total financing, including $63.5 million in Series B equity and a $20 million strategic credit facility to scale its precision diagnostics platform.
The company's proprietary platform uses a single blood draw to unlock genome-wide transcriptional biology (搜索) through advanced machine learning, targeting biomarkers for next-generation cancer (搜索) therapies including drug-, radio-, and immune-conjugates (搜索).
New investors include Labcorp Venture Fund (搜索), UPMC Enterprises (搜索), and Mirae Asset Capital, joining existing backers like Illumina Ventures (搜索) and Bristol Myers Squibb (搜索) to support the platform's commercial scaling.
Precede Biosciences (搜索) announced it has secured $83.5 million in total financing to accelerate the scaling of its precision diagnostics platform designed for next-generation cancer (搜索) therapies. The funding round includes $63.5 million in Series B equity and a $20 million strategic, non-dilutive credit facility.
The Boston-based company's platform addresses a critical need in precision medicine by supporting the development and clinical use of advanced cancer (搜索) therapies where target expression and pathway activity, rather than single genomic alterations, serve as defining biomarkers. These therapies include drug-, radio-, and immune-conjugates (搜索), as well as other advanced mono- and multi-specific targeted modalities.
Platform Technology and Clinical Application
Precede Bio's proprietary platform integrates a novel assay with advanced machine learning to unlock high-resolution, genome-wide transcriptional biology (搜索) from a single blood draw. Unlike conventional approaches that require different assays for individual targets or pathways, the company's platform utilizes a single, automated assay that resolves targets and pathways across the genome, enabling broad application across multiple indications.
"Precede Bio was purpose-built to ensure the reach and impact of the next wave of precision medicines," said Rehan Verjee, co-founder and CEO of Precede Bio. "We've started in cancer (搜索), where treatment decisions are inherently high-stakes, using a unique blood-based approach that enables access to target and pathway biology at the scale, speed, and accessibility modern patient care demands."
Market Opportunity and Clinical Need
The financing comes amid strong commercial traction with leading biopharmaceutical developers working on next-generation precision medicines. According to Wouter Meuleman, PhD, founding team member and Partner at Illumina Ventures (搜索), next-generation precision medicines represent a rapidly expanding therapeutic class, with novel binders in cancer (搜索), including drug-, radio-, and immune-conjugates (搜索), comprising the largest and fastest-growing segment with more than 1,500 therapies currently in development.
"That scale makes the need for diagnostic and data platforms built for broad application clear, reflecting a familiar evolution we saw in genomics as diagnostics moved from single-analyte to multiplex, and ultimately to blood-based approaches as targeted therapies expand," Meuleman explained.
Investor Syndicate and Strategic Partnerships
The Series B round includes continued support from existing investors and the addition of new strategic and institutional partners. New investors joining the syndicate include the Labcorp Venture Fund (搜索), UPMC Enterprises (搜索), Mirae Asset Capital Life Science, Mirae Asset Capital, 28 Capital, and Alexandria Venture Investments. Existing investors include Illumina Ventures (搜索), 5AM Ventures, Bristol Myers Squibb (搜索), Osage University Partners, Binney Street Capital, and Lilly Asia Ventures.
As part of the financing, Wouter Meuleman will join the Precede Bio Board of Directors. The expanded investor base adds partners with deep capabilities in diagnostics commercialization and health system adoption, alongside increased access to scaled, long-term capital.
Health System Integration and Future Impact
Matthias Kleinz, DVM, PhD, Executive Vice President at UPMC Enterprises (搜索), emphasized the platform's alignment with growing clinical needs. "As the number of next-generation precision medicines used in routine care continues to grow, health systems need better tools to ensure the right patients receive the right therapies," Kleinz said. "Precede Bio's platform is precisely aligned with this growing clinical need, and we believe it has the potential to meaningfully accelerate how these medicines reach and benefit patients."
The company's comprehensive epigenomics approach aims to enable researchers and clinicians to better understand disease biology in real time, working toward a future where drug development efforts succeed more frequently and patients receive minimally invasive diagnostics and treatments aligned to their disease biology.